Company profile for OcuTerra Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity. OcuTerra a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current st...
OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity. OcuTerra a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch and wait” does not prevent or control the progression of disease

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
50 Milk Street 16th Floor Boston MA 02109
Telephone
Telephone
(617) 701-7382
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

euroPLX 90 Lisbon

Not Confirmed

envelop Contact Supplier

euroPLX 90 Lisbon

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Phase 2 fail sends OcuTerra's eye drop dreams down the drain

14 Mar 2024

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/ph-2-fail-sends-ocuterras-eye-drop-dreams-down-drain

Gabrielle Masson FIERCE BIOTECH
14 Mar 2024

https://www.businesswire.com/news/home/20240104045633/en

BUSINESSWIRE
04 Jan 2024

https://www.businesswire.com/news/home/20240103754817/en

BUSINESSWIRE
03 Jan 2024

https://www.businesswire.com/news/home/20230718647783/en

BUSINESSWIRE
18 Jul 2023

https://www.businesswire.com/news/home/20230601005385/en

BUSINESSWIRE
01 Jun 2023

https://www.businesswire.com/news/home/20221019005275/en

BUSINESSWIRE
19 Oct 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty